Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

COMO: Cognition Study With HIV+ Patients (CTNPT 015) (COMO)

This study has been terminated.
(In 14 participants who had LP, very low level viremia was found in only 1)
Fonds de la Recherche en Santé du Québec
CIHR Canadian HIV Trials Network
Information provided by (Responsible Party):
Marie-Josée Brouillette, McGill University Health Center Identifier:
First received: March 29, 2014
Last updated: March 15, 2016
Last verified: March 2016
The purpose of this study is to contribute evidence towards the potential to improve cognition in HIV+ individuals experiencing cognitive decline through personalized change in antiretroviral (ARV) medication. To that end, following a comprehensive evaluation to identify confounding clinical conditions, study participants will undergo a lumbar puncture to: (i) measure viral load (at 2 copies/ml); (ii) identify Cerebrospinal Fluid (CSF) genotype and tropism; and (iii) measure concentration of antiretroviral agents. When indicated from the CSF analysis, a personalized change in ARV will be implemented. Cognition will be measured in all at study entry and 6 months later.

Condition Intervention Phase
HIV - Human Immunodeficiency Virus
Cognitive Symptoms
Drug: Change in antiretrovirals
Early Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: CTNPT 015 - Pilot Project to Implement a Step-wise Investigation That Includes Cerebrospinal (CSF) Analysis as a Standard of Care for HIV+ Individuals With Cognitive Symptoms

Resource links provided by NLM:

Further study details as provided by McGill University Health Center:

Primary Outcome Measures:
  • Changes in neurocognitive functioning over 6 months [ Time Frame: 6 months ]
    Cognition will be assessed at study entry and 6 months with the following tests: Letter Fluency, Category Fluency, Letter-Number Sequencing, Digit-Symbol, Symbol Search, Grooved Pegboard, Hopkins Verbal Learning Test-Revised, Stroop, Brief Visuospatial Memory Test-Revised, Tower of London, Trail Making Test A and B, Spatial Span, Montreal Cognitive Assessment (MoCA), and a brief computerized battery of tests (B-CAM).

Enrollment: 19
Study Start Date: June 2011
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Change in ARVs to improve cognition
Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
Drug: Change in antiretrovirals
Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • are 18 years and older
  • have the capacity to give informed consent as determined by the research nurse
  • have unexplained cognitive decline (reported either by the patient or an outside informant)
  • have been on a stable ART regimen for > 6 months
  • have an undetectable viral load in plasma for at least 6 months (a single blip of ≤ 150 copies/mL will be accepted)
  • have not had a change in medications that could potentially interfere with cognition in the past 4 months

Exclusion Criteria:

  • detectable VL in the plasma
  • past history of dementia
  • past history of Central Nervous System opportunistic infection or stroke
  • current substance abuse ( as per DSM-IV criteria) other than cigarettes
  • coagulopathy
  • thrombocytopenia
  • use of Coumadin
  • intra-cranial hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02144688

Canada, Quebec
Montreal Chest Institute - Chronic Viral Illness Service - McGill University Health Centre (MUHC)
Montreal, Quebec, Canada, H2X 2P4
Sponsors and Collaborators
Marie-Josée Brouillette
Fonds de la Recherche en Santé du Québec
CIHR Canadian HIV Trials Network
Principal Investigator: Marie-Josée Brouillette, MD, FRCPC Montreal Chest Institute - Chronic Viral Illness Service - McGill University Health Centre (MUHC)
  More Information

Additional Information:

Responsible Party: Marie-Josée Brouillette, Associate Professor, McGill University Health Center Identifier: NCT02144688     History of Changes
Obsolete Identifiers: NCT01848678
Other Study ID Numbers: CTNPT 015
Study First Received: March 29, 2014
Last Updated: March 15, 2016
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by McGill University Health Center:
Human Immunodeficiency Virus
Cognitive symptoms
Cognitive evaluation
Neuropsychological testing
Quality of life
Viral load
Cerebrospinal fluid
Lumbar puncture
Magnetic resonance imaging

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Neurobehavioral Manifestations
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms processed this record on May 23, 2017